Clincosm LogoSign in Get a demo

Thyroid Hormones Effect on Brown Adipose Tissue

Sponsor
Huashan Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT01376648
Collaborator
(none)
20
Enrollment
1
Location
29
Duration (Months)
0.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Brown adipose tissue (BAT) is important in energy expenditure through thermogenesis although the regulatory factors are not well known in humans. There is evidence suggesting that the thyroid hormones affect BAT functions in lower mammals, but the effects of the thyroid hormones on BAT activity in humans are still unclear. The objective of this study was to investigate the effects of thyroid hormones on glucose metabolism of BAT and other organs in humans.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Twenty consecutive patients with Graves'-caused hyperthyroidism who are newly diagnosed and untreated will be studied at the Endocrine Department of Huashan Hospital, Fudan University. All subjects are screened and examined by two senior investigators. Putative BAT activity is determined by the integrated 18F-fluorodeoxyglucose (18F-FDG) PET-CT. After the first PET scan, hyperthyroid patients will be treated with Methimazole following clinical guidelines. None of them uses beta adrenergic blockade. The initial dose of methimazole employed is 10mg thrice a day. During follow-up, the thyroid hormone levels (free triiodothyronine and free thyroxine) will be measured every twenty days. The PET-CT scans and assessments will be repeated when the symptoms have disappeared and the thyroid hormone levels return to normal range. Then the dose of methimazole will be adjusted accordingly.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    20 participants
    Time Perspective:
    Prospective
    Official Title:
    Study on the Relationship Between the Thyroid Hormones and the Activity of Brown Adipose Tissue in Human
    Study Start Date :
    Dec 1, 2009
    Anticipated Primary Completion Date :
    May 1, 2012
    Anticipated Study Completion Date :
    May 1, 2012

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      18 Years and Older
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      No
      Inclusion Criteria:

      • Newly diagnosed and untreated hyperthyroid patients

      • Informed consent was obtained

      Exclusion Criteria:

      • History of other endocrine diseases

      • Useing beta adrenergic blockade

      • Pregnant women

      • Pacemaker implantation

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 Huashan Hospital Shanghai China 200040

      Sponsors and Collaborators

      • Huashan Hospital

      Investigators

      • Study Chair: Yiming Li, Dr., Huashan Hospital

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      , ,
      ClinicalTrials.gov Identifier:
      NCT01376648
      Other Study ID Numbers:
      • KY2009-257
      First Posted:
      Jun 20, 2011
      Last Update Posted:
      Jun 20, 2011
      Last Verified:
      Nov 1, 2009
      Additional relevant MeSH terms:
      Hyperthyroidism

      Study Results

      No Results Posted as of Jun 20, 2011